Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation of Georges Ugeux from Board of Directors
Date:9/23/2009

DETROIT, Sept. 23 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) announced that on September 20, 2009, Georges Ugeux resigned as a director of the Company and from the audit, compensation and independent committees of the Board. Mr. Ugeux was the chairman of the independent committee.

In his resignation letter, Mr. Ugeux indicated that he had disagreements with the majority shareholder and senior management of the Company relating to corporate governance and the fiduciary role of independent directors. The Company believes that Mr. Ugeux's disagreements relate to the role of the independent directors going forward in managing the FDA actions previously disclosed by the Company. The current Board, including all the independent directors, believe that management of the FDA actions is and should remain the top priority and focus for the entire management team of the Company, with the entire Board providing the necessary oversight.

All of the members of the current Board, including the independent directors, believe that all shareholders' interests are aligned, and that the Company is moving in the right direction to enable it to resolve the FDA's concerns as expeditiously as possible. In this connection, the Company has engaged highly regarded (i) special FDA counsel to negotiate with the FDA on behalf of the Company and (ii) FDA consultants who are advising and will advise the Company with respect to compliance with FDA requirements. The Board is focused and resolute in its desire to resolve the FDA's concerns, and believes that it is acting in the best interests of all of the Company's shareholders, as resolution of such concerns will benefit all of the shareholders of the Company.

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limitation, the words "believe" or "expect" and similar expressions are intended to identify forward-looking statements. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission, including Part I, Item 1A of our most recent Form 10-K, and include but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or less expensive products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, material litigation from product recalls, the purported class action lawsuits alleging federal securities laws violations, delays in returning the Company's products to market, including loss of market share, increased reserves against the FDA-seized inventory, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
4. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
5. Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008
6. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lamictal(R)
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Tentative FDA Approval for Generic Lexapro(R)
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Norvasc(R)
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Childrens Zyrtec(R) Chewable Tablets for Allergy Relief and Childrens Zyrtec(R) Chewable Tablets for Hives Relief
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Metaglip(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... VA (PRWEB) , ... February 09, 2016 , ... On ... The family scheduled an appointment after they noticed their furnace not producing any heat. ... cracked heat exchanger. The cracked heat exchanger was leaking dangerous levels of carbon monoxide ...
(Date:2/9/2016)... ... February 09, 2016 , ... Dr. Rassouli, cosmetic ... Teeth whitening is among the most popular cosmetic procedures in dentistry today, but the ... This can put them at risk of teeth whitening-related damage. For a limited time, ...
(Date:2/9/2016)... ... 09, 2016 , ... IsoComforter, Inc., one of the Nation’s ... designed, innovative shoulder wrap. The newly designed shoulder wrap has been specifically ... and shoulder to promote faster healing. It is highly recommended for arm or ...
(Date:2/9/2016)... ... 09, 2016 , ... Sir Grout, the leading hard surface ... announce that many of their franchises have received the Super Service Award from ... franchises received customer recognition through positive reviews and testimonials, as well as evaluations ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Brain Preservation Foundation’s (BPF) ... from 21st Century Medicine (21CM) ( http://www.21cm.com/ ), spearheaded by recent MIT ... of an intact rabbit brain for extremely long-term storage using a combination of ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... -- This TforG report includes the Surgical Procedures Database ... system in South Korea . To ... provides written and numerical analysis on the current trends, ... the latest reforms of the local Healthcare system are ... The report helps businesses gain a unique insight ...
(Date:2/9/2016)... BRUNSWICK, N.J. , Feb. 9, 2016  Johnson ... the RBC Capital Markets Global Healthcare Conference on Tuesday, ... York City.  Dominic Caruso , Vice President, Finance ... Worldwide Chairman, Consumer will represent the Company in a ... www.investor.jnj.com . --> www.investor.jnj.com . ...
(Date:2/9/2016)... report "Global Anti-Bacterial Drugs Market Assessment & Forecast: 2015 - 2019" ... North America continued to lead global anti-bacterial ... into revenues worth US$ 16,907.3 million. North ... , Latin America , Middle-East ... market is inclined towards North America and ...
Breaking Medicine Technology: